Home Applications 203389 Application 203389
Type NDA
Sponsor HORIZON PHARMA USA Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 PROCYSBI CYSTEAMINE BITARTRATE CAPSULE, DELAYED RELEASE;ORAL EQ 25MG BASE Yes No 002 PROCYSBI CYSTEAMINE BITARTRATE CAPSULE, DELAYED RELEASE;ORAL EQ 75MG BASE Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N203389-001 PROCYSBI CYSTEAMINE BITARTRATE EQ 25MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD 2013-04-30 N203389-002 PROCYSBI CYSTEAMINE BITARTRATE EQ 75MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD, RS 2013-04-30
Orange Book patents# Current patent rows page 1 of 1 · 48 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 3 of 3 · 88 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N203389-001 PROCYSBI EQ 25MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD 2013-04-30 f41ea6bd6efb…2022-10-28 04:53 UTC 2022-10 N203389-002 PROCYSBI EQ 75MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD, RS 2013-04-30 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N203389-001 PROCYSBI EQ 25MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD 2013-04-30 e64feba35796…2022-09-29 23:25 UTC 2022-09 N203389-002 PROCYSBI EQ 75MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD, RS 2013-04-30 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N203389-001 PROCYSBI EQ 25MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD 2013-04-30 cb3db0bc1861…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N203389-002 PROCYSBI EQ 75MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD, RS 2013-04-30 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N203389-001 PROCYSBI EQ 25MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD 2013-04-30 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N203389-002 PROCYSBI EQ 75MG BASE CAPSULE, DELAYED RELEASE / ORAL RLD, RS 2013-04-30 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 48 · 1,892 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N203389-001 9192590 2027-01-26 U-1399 2015-11-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9198882 2027-01-26 U-1399 2015-12-02 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9925156 2027-01-26 U-1399 Drug substance, Drug product 2018-04-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9925157 2027-01-26 U-1399 Drug substance, Drug product 2018-04-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9925158 2027-01-26 U-1399 Drug substance, Drug product 2018-04-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9192590*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9198882*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9925156*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9925157*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9925158*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 8026284 2027-09-22 U-1399 2013-05-24 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 8026284*PED 2028-03-22 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9173851 2034-06-17 Drug product 2015-11-04 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9233077 2034-06-17 Drug product 2016-01-13 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9173851*PED 2034-12-17 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 9233077*PED 2034-12-17 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 10143665 2036-08-16 U-1399 2018-12-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 10328037 2036-08-16 U-1399 2019-07-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 10548859 2036-08-16 U-1399 2020-03-04 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 10905662 2036-08-16 U-1399 2021-03-02 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 10143665*PED 2037-02-16 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 10328037*PED 2037-02-16 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 10548859*PED 2037-02-16 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-001 10905662*PED 2037-02-16 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9192590 2027-01-26 U-1399 2015-11-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9198882 2027-01-26 U-1399 2015-12-02 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9925156 2027-01-26 U-1399 Drug substance, Drug product 2018-04-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9925157 2027-01-26 U-1399 Drug substance, Drug product 2018-04-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9925158 2027-01-26 U-1399 Drug substance, Drug product 2018-04-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9192590*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9198882*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9925156*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9925157*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9925158*PED 2027-07-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 8026284 2027-09-22 U-1399 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 8026284*PED 2028-03-22 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9173851 2034-06-17 Drug product 2015-11-04 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9233077 2034-06-17 Drug product 2016-01-13 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9173851*PED 2034-12-17 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203389-002 9233077*PED 2034-12-17 Pediatric extension c2088c7a36db…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 7 · 266 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 14 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 75987-100 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-100 PROCYSBI Cysteamine bitartrate Horizon Pharma Inc. NDA Current 75987-100 PROCYSBI Cysteamine bitartrate Horizon Pharma Inc. NDA Current 75987-100 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-100 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-100 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-100 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-101 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-101 PROCYSBI Cysteamine bitartrate Horizon Pharma Inc. NDA Current 75987-101 PROCYSBI Cysteamine bitartrate Horizon Pharma Inc. NDA Current 75987-101 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-101 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-101 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-101 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current